Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Yukio Numata"'
Publikováno v:
PLoS ONE, Vol 9, Iss 6, p e100634 (2014)
Remission is the primary goal of treatment for bipolar disorder I (BDI). Metabolites of noradrenaline and dopamine, 3-methoxy-4-hydroxyphenylglycol (MHPG) and homovanillic acid (HVA), respectively, are reduced by treatment with antipsychotics, but wh
Externí odkaz:
https://doaj.org/article/d900f13dcf734046881e21f1b66c92ed
Publikováno v:
PLoS ONE, Vol 7, Iss 6, p e39212 (2012)
UNLABELLED: Remission is the primary goal of treatment for major depressive disorder (MDD). However, some patients do not respond to treatment. The main purpose of this study was to determine whether brain-derived neurotrophic factor (BDNF) levels ar
Externí odkaz:
https://doaj.org/article/b2070fb3b3964888b4f8b41208ecf0f8
Publikováno v:
XIX ENCONTRO NACIONAL DE TECNOLOGIA DO AMBIENTE CONSTRUÍDO.
Fast Construction é caracterizada pelo curto prazo de execução, alta qualidade e jornadas de trabalho no período noturno. Conhecer ferramentas que resultem na melhoria da gestão aumentam as chances de sucesso do projeto. Por isso, o objetivo des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ce64be40343725604ce614699606446
https://doi.org/10.46421/entac.v19i1.2171
https://doi.org/10.46421/entac.v19i1.2171
Publikováno v:
Neuropsychiatric Disease and Treatment
Masatake Kurita,1–3 Satoshi Nishino,1,2 Yukio Numata,1 Yoshiro Okubo,3 Tadahiro Sato11Sato Hospital, Koutokukai, Nanyo, Yamagata, Japan; 2Department of Cellular Signaling, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::488ce4a398ca50f37231a268cfe34bb4
http://europepmc.org/articles/PMC4334324
http://europepmc.org/articles/PMC4334324
Autor:
Yukio Numata, Masatake Kurita, Norimichi Nakahata, Koji Ohtomo, Satoshi Nishino, Tadahiro Sato
Publikováno v:
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 39:17-22
Mood stabilizers such as lithium (Li) or valproic acid (VPA) are used in the therapy of bipolar disorders, but the mechanisms by which these medicines work is unclear. Recently, neuroprotection has attracted attention as a potential action for VPA an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ce21aaa10ad58baeb57d8cf40d806ec
https://doi.org/10.1016/j.pnpbp.2011.07.008
https://doi.org/10.1016/j.pnpbp.2011.07.008
Autor:
Yukio Numata, Yoshiro Okubo, Amane Tateno, Tadahiro Sato, Satoshi Nishino, Kenji Takeyoshi, Mika Teranishi, Masatake Kurita
Publikováno v:
Journal of clinical psychopharmacology. 33(5)
The descriptive term behavioral and psychological symptoms of dementia (BPSD) is used to cover a range of noncognitive disturbances including anxiety, depression, irritability, aggression, agitation, eating disorders, and inappropriate social or sexu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::358ed0b450bcd83f43f77809f11d1317
https://pubmed.ncbi.nlm.nih.gov/23948783
https://pubmed.ncbi.nlm.nih.gov/23948783
Autor:
Mika Teranishi, Kenji Takeyoshi, Masatake Kurita, Satoshi Nishino, Yoshiro Okubo, Tadahiro Sato, Yukio Numata
Publikováno v:
Neuropsychiatric Disease and Treatment
Kenji Takeyoshi,1,2 Masatake Kurita,1–3 Satoshi Nishino,2,3 Mika Teranishi,1 Yukio Numata,2 Tadahiro Sato,2 Yoshiro Okubo11Department of Psychiatry and Behavioral Science, Graduate School of Medicine, Nippon Medical School, Bunkyo-ku, Tokyo, 2Sato
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86e82b8ab7da8aaecd8e773a5d8e3701
https://doi.org/10.2147/ndt.s99032
https://doi.org/10.2147/ndt.s99032
Publikováno v:
PLoS ONE
PLoS ONE, Vol 9, Iss 6, p e100634 (2014)
PLoS ONE, Vol 9, Iss 6, p e100634 (2014)
Remission is the primary goal of treatment for bipolar disorder I (BDI). Metabolites of noradrenaline and dopamine, 3-methoxy-4-hydroxyphenylglycol (MHPG) and homovanillic acid (HVA), respectively, are reduced by treatment with antipsychotics, but wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7c1be2d4c14e243815f33a6c1624acc
https://doi.org/10.1371/journal.pone.0100634
https://doi.org/10.1371/journal.pone.0100634
Autor:
Kenji Takeyoshi, Masatake Kurita, Satoshi Nishino, Mika Teranishi, Yukio Numata, Tadahiro Sato, Yoshiro Okubo
Publikováno v:
Neuropsychiatric Disease & Treatment; Mar2016, Vol. 12, p641-649, 9p
Publikováno v:
PLoS ONE
PLoS ONE, Vol 7, Iss 6, p e39212 (2012)
PLoS ONE, Vol 7, Iss 6, p e39212 (2012)
UNLABELLED: Remission is the primary goal of treatment for major depressive disorder (MDD). However, some patients do not respond to treatment. The main purpose of this study was to determine whether brain-derived neurotrophic factor (BDNF) levels ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff67efcd71d44e384ea678e471cf82b3
https://doi.org/10.1371/journal.pone.0039212
https://doi.org/10.1371/journal.pone.0039212